Heart Failure Therapy in Patients with Diabetes The new Benefit-Risk-Assessment of Sacubitril/Valsartan

Vincent Matthias Brandenburg*, Hanspeter Brunner-La Rocca*, Nikolaus Marx*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Sacubitril / Valsartan proofed to be an effective treatment compared to enalapril in reducing heart failure hospitalisations and mortality in patients with severe "Heart failure with reduced ejection fraction" (HFREF). Recent European cardiology guidelines attributed a class IB recommendation for Sacubitril / Valsartan in HFREF patients who remain symptomatic despite optimal treatment with ACE-I, a beta-blocker, and a mineralocorticoid receptor antagonist. There is a significant overlap between diabetic and HFREF patients and thus, efficacy assessment of Sacubitril / Valsartan is a clinically meaningful issue in the large subgroup of HFREF patients with diabetes. We discuss the present evidence why local authorities speculated about a potential interaction between the two diseases decreasing the efficacy of sacubitril/valsartan in terms of reducing relevant end-points in this cohort. Overall, Sacubitril / Valsartan is obviously a treatment option in diabetics with HFREF. However, diabetic cardiomyopathy needs to be recognised as a specific disease condition.? Georg Thieme Verlag KG Stuttgart ? New York.
Original languageEnglish
Pages (from-to)1647-1649
JournalDeutsche Medizinische Wochenschrift
Issue number22
Publication statusPublished - Oct 2016


Dive into the research topics of 'Heart Failure Therapy in Patients with Diabetes The new Benefit-Risk-Assessment of Sacubitril/Valsartan'. Together they form a unique fingerprint.

Cite this